CRS‐related cytokines including IL‐6, IL‐10, sCD25, TNF‐γ and SF quickly decreased in these four patients after ruxolitinib intervention, which implicates that ruxolitinib successfully stops these cytokines release. Here, IL6 is linked to congenital rubella syndrome.